FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999979428> ?p ?o ?g. }

• W1999979428 endingPage "987" @default.
• W1999979428 startingPage "975" @default.
• W1999979428 abstract "Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats.BackgroundOver 54 generations, we have successfully bred a strain of rats that maximizes urinary calcium excretion. The rats now consistently excrete 8 to 10 times as much calcium as controls, uniformly form poorly crystalline calcium phosphate kidney stones, and are termed genetic hypercalciuric stone-forming (GHS) rats. These rats were used to test the hypothesis that increasing urinary oxalate excretion would not only increase the supersaturation with respect to the calcium oxalate solid phase, but also would increase the ratio of calcium oxalate-to-calcium phosphate supersaturation and result in calcium oxalate stone formation.MethodsTo increase urine oxalate excretion an oxalate precursor, hydroxyproline, was added to the diet of male GHS rats. The GHS rats were fed a standard 1.2% calcium diet alone or with 1%, 3% or 5% trans-4-hydroxy-L-proline (hydroxyproline).ResultsThe addition of 1% hydroxyproline to the diet of GHS rats led to an increase in urinary oxalate excretion, which did not increase further with the provision of additional hydroxyproline. The addition of 1% and 3% hydroxyproline did not alter calcium excretion while the provision of 5% hydroxyproline led to a decrease in urine calcium excretion. The addition of 1% hydroxyproline led to an increase in urinary calcium oxalate supersaturation, which did not further increase with additional hydroxyproline. The addition of 1% and 3% hydroxyproline did not alter urinary supersaturation with respect to calcium hydrogen phosphate while the addition of 5% hydroxyproline tended to lower this supersaturation. Compared to rats fed the control and the 3% hydroxyproline diet the addition of 5% hydroxyproline increased the ratio of calcium oxalate supersaturation to calcium phosphate supersaturation. Virtually all rats formed stones. In the control and 1% hydroxyproline group, all of the stones were composed of calcium and phosphate (apatite), in the 3% hydroxyproline group the stones were a mixture of apatite and calcium oxalate, while in the 5% hydroxyproline group all of the stones were calcium oxalate.ConclusionsThe provision of additional dietary hydroxyproline to GHS rats increases urinary oxalate excretion, calcium oxalate supersaturation and the ratio of calcium oxalate-to-calcium phosphate supersaturation, resulting in the formation of calcium oxalate kidney stones. Thus, with the addition of a common amino acid, the GHS rats now not only model the most common metabolic abnormality found in patients with nephrolithiasis, hypercalciuria, but form the most common type of kidney stone, calcium oxalate. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Over 54 generations, we have successfully bred a strain of rats that maximizes urinary calcium excretion. The rats now consistently excrete 8 to 10 times as much calcium as controls, uniformly form poorly crystalline calcium phosphate kidney stones, and are termed genetic hypercalciuric stone-forming (GHS) rats. These rats were used to test the hypothesis that increasing urinary oxalate excretion would not only increase the supersaturation with respect to the calcium oxalate solid phase, but also would increase the ratio of calcium oxalate-to-calcium phosphate supersaturation and result in calcium oxalate stone formation. To increase urine oxalate excretion an oxalate precursor, hydroxyproline, was added to the diet of male GHS rats. The GHS rats were fed a standard 1.2% calcium diet alone or with 1%, 3% or 5% trans-4-hydroxy-L-proline (hydroxyproline). The addition of 1% hydroxyproline to the diet of GHS rats led to an increase in urinary oxalate excretion, which did not increase further with the provision of additional hydroxyproline. The addition of 1% and 3% hydroxyproline did not alter calcium excretion while the provision of 5% hydroxyproline led to a decrease in urine calcium excretion. The addition of 1% hydroxyproline led to an increase in urinary calcium oxalate supersaturation, which did not further increase with additional hydroxyproline. The addition of 1% and 3% hydroxyproline did not alter urinary supersaturation with respect to calcium hydrogen phosphate while the addition of 5% hydroxyproline tended to lower this supersaturation. Compared to rats fed the control and the 3% hydroxyproline diet the addition of 5% hydroxyproline increased the ratio of calcium oxalate supersaturation to calcium phosphate supersaturation. Virtually all rats formed stones. In the control and 1% hydroxyproline group, all of the stones were composed of calcium and phosphate (apatite), in the 3% hydroxyproline group the stones were a mixture of apatite and calcium oxalate, while in the 5% hydroxyproline group all of the stones were calcium oxalate. The provision of additional dietary hydroxyproline to GHS rats increases urinary oxalate excretion, calcium oxalate supersaturation and the ratio of calcium oxalate-to-calcium phosphate supersaturation, resulting in the formation of calcium oxalate kidney stones. Thus, with the addition of a common amino acid, the GHS rats now not only model the most common metabolic abnormality found in patients with nephrolithiasis, hypercalciuria, but form the most common type of kidney stone, calcium oxalate." @default.
• W1999979428 created "2016-06-24" @default.
• W1999979428 creator A5004257005 @default.
• W1999979428 creator A5004739946 @default.
• W1999979428 creator A5015891160 @default.
• W1999979428 creator A5021392423 @default.
• W1999979428 creator A5069066834 @default.
• W1999979428 creator A5091430658 @default.
• W1999979428 creator A5091483213 @default.
• W1999979428 date "2002-03-01" @default.
• W1999979428 modified "2023-10-10" @default.
• W1999979428 title "Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats" @default.
• W1999979428 cites W1234732706 @default.
• W1999979428 cites W1527182411 @default.
• W1999979428 cites W1938785381 @default.
• W1999979428 cites W1963643568 @default.
• W1999979428 cites W1964103204 @default.
• W1999979428 cites W1969799515 @default.
• W1999979428 cites W1974662459 @default.
• W1999979428 cites W1979143508 @default.
• W1999979428 cites W1984496590 @default.
• W1999979428 cites W1984960056 @default.
• W1999979428 cites W1990715146 @default.
• W1999979428 cites W2005296604 @default.
• W1999979428 cites W2012349916 @default.
• W1999979428 cites W2021980809 @default.
• W1999979428 cites W2027312479 @default.
• W1999979428 cites W2028356835 @default.
• W1999979428 cites W2043096939 @default.
• W1999979428 cites W2052357540 @default.
• W1999979428 cites W2053605231 @default.
• W1999979428 cites W2058624573 @default.
• W1999979428 cites W2061982739 @default.
• W1999979428 cites W2062431829 @default.
• W1999979428 cites W2073247464 @default.
• W1999979428 cites W2078278754 @default.
• W1999979428 cites W2078948216 @default.
• W1999979428 cites W2079235616 @default.
• W1999979428 cites W2080838084 @default.
• W1999979428 cites W2082282584 @default.
• W1999979428 cites W2086044276 @default.
• W1999979428 cites W2139640966 @default.
• W1999979428 cites W2168187347 @default.
• W1999979428 cites W2224297597 @default.
• W1999979428 cites W2313856264 @default.
• W1999979428 cites W2340504819 @default.
• W1999979428 cites W2343969664 @default.
• W1999979428 cites W2396338222 @default.
• W1999979428 cites W2467507680 @default.
• W1999979428 cites W2642355309 @default.
• W1999979428 cites W4210738506 @default.
• W1999979428 cites W4238319848 @default.
• W1999979428 cites W4239323818 @default.
• W1999979428 cites W4254539431 @default.
• W1999979428 cites W4298172034 @default.
• W1999979428 cites W4361868858 @default.
• W1999979428 cites W6323710 @default.
• W1999979428 cites W98321654 @default.
• W1999979428 doi "https://doi.org/10.1046/j.1523-1755.2002.00190.x" @default.
• W1999979428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11849452" @default.
• W1999979428 hasPublicationYear "2002" @default.
• W1999979428 type Work @default.
• W1999979428 sameAs 1999979428 @default.
• W1999979428 citedByCount "100" @default.
• W1999979428 countsByYear W19999794282012 @default.
• W1999979428 countsByYear W19999794282013 @default.
• W1999979428 countsByYear W19999794282014 @default.
• W1999979428 countsByYear W19999794282015 @default.
• W1999979428 countsByYear W19999794282016 @default.
• W1999979428 countsByYear W19999794282017 @default.
• W1999979428 countsByYear W19999794282018 @default.
• W1999979428 countsByYear W19999794282019 @default.
• W1999979428 countsByYear W19999794282020 @default.
• W1999979428 countsByYear W19999794282021 @default.
• W1999979428 countsByYear W19999794282022 @default.
• W1999979428 countsByYear W19999794282023 @default.
• W1999979428 crossrefType "journal-article" @default.
• W1999979428 hasAuthorship W1999979428A5004257005 @default.
• W1999979428 hasAuthorship W1999979428A5004739946 @default.
• W1999979428 hasAuthorship W1999979428A5015891160 @default.
• W1999979428 hasAuthorship W1999979428A5021392423 @default.
• W1999979428 hasAuthorship W1999979428A5069066834 @default.
• W1999979428 hasAuthorship W1999979428A5091430658 @default.
• W1999979428 hasAuthorship W1999979428A5091483213 @default.
• W1999979428 hasBestOaLocation W19999794281 @default.
• W1999979428 hasConcept C10146269 @default.
• W1999979428 hasConcept C126322002 @default.
• W1999979428 hasConcept C134018914 @default.
• W1999979428 hasConcept C178790620 @default.
• W1999979428 hasConcept C179104552 @default.
• W1999979428 hasConcept C185592680 @default.
• W1999979428 hasConcept C200447597 @default.
• W1999979428 hasConcept C2776179656 @default.
• W1999979428 hasConcept C2776351790 @default.
• W1999979428 hasConcept C2776697488 @default.
• W1999979428 hasConcept C2777724520 @default.
• W1999979428 hasConcept C2779403450 @default.
• W1999979428 hasConcept C2779797417 @default.

• next